# Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

> **NCT00041808** · PHASE1,PHASE2 · COMPLETED · sponsor: **FeRx** · enrollment: 20 (—)

## Conditions studied

- Metastases, Neoplasm
- Colorectal Neoplasms
- Esophageal Neoplasms
- Stomach Neoplasms
- Pancreatic Neoplasms
- Breast Neoplasms
- Melanoma
- Sarcoma
- Gastrointestinal Neoplasms
- Lung Neoplasms
- Liver Neoplasms
- Cholangiocarcinoma

## Interventions

- **DRUG:** MTC-DOX for Injection
- **PROCEDURE:** Chemotherapy

## Key facts

- **NCT ID:** NCT00041808
- **Lead sponsor:** FeRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2003-04
- **Target enrollment:** 20 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041808, "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00041808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*